摘要
托法替尼(Tofacitinib)是一种口服Janus激酶(JAK)抑制剂,能够阻断JAK/STAT信号转导通路减少多种细胞因子的生成与释放。已被美国食品和药品监督管理局和欧盟药品管理局批准用于治疗对MTX或其他抗风湿病药物(DMARDs)反应不足或不耐受的成人活动性关节病型银屑病(PsA)患者。PsA是一种慢性免疫介导的全身性炎症性疾病,大多数参与PsA发病的细胞因子与受体结合后,JAK结合于受体胞内部分并激活信号转导与转录激活因子(STAT)蛋白介导的细胞内信号通路,引起促炎细胞因子的基因转录。现已证明托法替尼治疗PsA安全、有效,且显示出与生物制剂相当的疗效。本文就托法替尼治疗PsA的研究进展进行综述。
Tofacitinib is an oral Janus kinase(JAK)inhibitor,which can block JAK/STAT signal transduction pathway and reduce the production and release of a variety of cytokines.It has been approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of active adult patients with psoriatic arthritis(PsA)who are inadequate or intolerant to methotrexate or other antirheumatic drugs(DMARDs).PsA is a chronic immune-mediated systemic inflammatory disease.After the majority of cytokines involved in the pathogenesis of PsA bind to the receptor,JAK binds to the intracellular part of the recipient and activates the intracellular signal pathway mediated by signal transducer and transcriptional activator(STAT)protein,resulting in pro-inflammatory cytokine gene transcription.It has been proved that tofacitinib is safe and effective in the treatment of PsA,showing the similar efficacy compared with biologic agents.The research progress of tofacitinib in the treatment of PsA is reviewed in this article.
作者
高英丽
栗玉珍
GAO Yingli;LI Yuzhen(Department of Dermatology,The Second Affiliated Hospital of Harbin Medical University,Harbin 150000,China)
出处
《中国麻风皮肤病杂志》
2021年第6期402-405,共4页
China Journal of Leprosy and Skin Diseases
基金
国家自然科学基金(编号:81773320)。
